



connections newsletter



**NOV 2020
UPDATE**

**Serving the NC Life
Sciences Industry**

<http://ncbioscience.net>
919-281-8960

[home](#) | [about](#) | [calendar](#) | [news](#) | [member benefits](#) | [forums](#) | [advocacy](#) | [contact](#)

NCBIO This Month

- Life Science Caucus Hears about Growth in NC Life Science Sector
- Innovation, Policy, Elections & More During NCBIO Virtual Annual Meeting
- NCBIO Forum on COVID-19 and Clinical Trials
- Virtual Forum, BIO Business Solutions Spotlight
- Series on Diversity in Life Science
- One Small Business Fund SBIR Matching Grants Available, Apply by Dec 1
- First Flight Venture Center Wins Federal Award
- AdvanSE Life Sciences Virtual Conference Nov 9- 13



- [At the National Level](#)
- [Member News](#)
- [Member Benefits](#)
- [Calendar](#)

Life Science Caucus Hears about Growth in NC Life Science Sector

Two companies locating to North Carolina, Lilly and GRAIL, and North Carolina Biotechnology Center (NCBiotech) leaders made presentations about growing the life science industry in the State during the October Legislative Life Science Caucus meeting. Doug Edgeton, President and CEO of NCBiotech, talked about biomanufacturing companies locating in NC as well as the growth of start-up and midsize companies, noting the need for more capital investments. He recognized the work of NC companies in developing tests, treatments and solutions for COVID-19. Reviewing the NC Life Sciences 2025 Initiative, Edgeton spoke to four areas of interest: Talent, Infrastructure, Investment and Market Attraction.

Bill Bullock who leads recruitment efforts for NCBiotech reviewed the recent announcement of companies locating or expanding in the state. He said, "Biotech is on rise in NC and highlights a big opportunity for North Carolina."

NCBIO - Media

Find the latest news from NCBIO on the website ncbioscience.net, on [LinkedIn](#) and on Twitter at [@ncbio](#).

NCBIO Links

[CED](#)

[NCBIO](#)

[NC Biotech Center](#)

[BRITE](#)

[BTEC](#)

[BioNetwork](#)

[NCBioImpact](#)

[North Carolina
Pharmaceutical Services
Network](#)

[NCABR](#)

[National Center for
Biotechnology Workforce](#)


NCBIO Sustaining Members

[Bio](#)



Company Confidential © 2020 Eli Lilly and Company

Dan VonDielingen, Site Head for the new Lilly facility, outlined plans for the manufacturing plant. He noted that workforce capability, education institutions, state incentives and public policies were just a few of the reasons Lilly was locating a facility here. The site will be Lilly's first manufacturing facility outside of the Midwest and will be a distribution site for the Southeast.



Joan Malcolm, Director of External Affairs at GRAIL, discussed the multi-cancer early detection screening tests that will be produced in RTP. She noted the importance of detecting cancer earlier to help with the survivable rates for patients. She too recognized the environment created in North Carolina "to help innovators serve patients faster."

Caucus Co-Chairs, Sen. Paul Newton, Sen. Mike Woodward, Rep. Donna McDowell White and Rep. Robert Reives talked with the companies about the bipartisan work to ensure the industry continues to create jobs. A lively discussion around the role and opportunity for community colleges ensued and as a next step, the Caucus members asked for more information on ways to improve capital investment in NC small and mid-size companies.

For more information about NC BIO's work with the Caucus, contact [Laura Gunter](#).

[Back to top.](#)



Biogen



Lilly



Pfizer



We Work For Health



NCBIO Supporting Members

Cook Medical



Grail



Merck



Novartis



VWR





BIO's new CEO and President Michelle McMurry-Heath told NCBIO members, "We are living through extraordinary challenges," during the closing session. "I hope it is a turning point in the public's understanding of why science matters. Biotech and science are the catalysts that will ensure we come out of this pandemic stronger, healthier and more resilient." NCBIO's [26th Annual Meeting](#) was held virtually Tuesday, September 29 to Friday, October 2 from noon to 1:30 p.m.

McMurry-Heath also discussed the BioEquality Agenda to create a more inclusive and diverse healthcare ecosystem and emphasized the importance of voting and having a voice in the federal drug pricing debate.

As part of the session, BIO recognized North Carolina Governor Roy Cooper as BIO's 2020 Governor of the Year. In accepting the award, Governor Cooper noted NC has become a home for cell and gene therapy manufacturing, and last year the state worked with the industry creating 3600 new jobs. "Innovations in the life sciences are transforming the way we approach treating diseases, environmental sustainability and food production. North Carolina biotechnology companies have led the way to getting us faster diagnostic testing, treatments and new vaccines as we work toward preventing and curing diseases."

- **Dave Thomas**, Vice President of Industry Research, Biotechnology Innovation Organization (BIO)
- **Michelle McMurry-Heath, M.D., Ph.D.**, President and Chief Executive Officer, BIO



Sponsored by  **bioventus**
Active Healing Through Orthobiologics

 **FUJIFILM**
Di-synth
biotechnologies

Also during the closing, BIO Vice President of Industry Analysis Dave Thomas reviewed the industry response to COVID-19, noting that over half of the 764 unique drug programs have originated in the US and 72% are by small companies. He said 2020 will likely be a banner year for raising capital for the industry.

FIRESIDE CHAT

- **Laura Gunter**, Membership Development Director & Government Affairs, NCBIO (moderator)
- **Morgan Jackson**, Co-Founder and Partner, Nexus Strategies
- **Paul Shumaker**, Founder and President, Capitol Communications

Sponsored by  Biotechnology Innovation Organization 



NCBIO Membership and Government Affairs Director Laura Gunter moderated a lively discussion with Democratic Consultant Morgan Jackson of Nexus Strategies and Republican Consultant Paul Shumaker of Capitol Communications during the opening session. Jackson and Shumaker discussed the competitiveness of statewide campaigns in 2020 and the change in campaign activity because of COVID-19. Both stated that North Carolina is a swing state with both Presidential and US Senate candidates spending millions on advertising to appeal to the undecided voters.

Jackson and Shumaker stated that health care and drug pricing are major issues in campaigns. Jackson stated, “Most people have a hard time grasping how expensive it is to get a drug to market, and that everyone wants lower prescription drug costs.” Shumaker says the industry needs “to be strategic in getting its message out and reaching the grassstops and the grassroots,” those making the decisions and those voting on the decisionmakers. He noted candidates on both sides of the political spectrum are pushing for lower drug prices. Both said the industry needs to be part of the solution in lowering prices.

National Policy Outlook & Ramifications

Introduction by **Brian Stoker**, Manager, Corporate Affairs, **Grifols**

Fireside Chat

- **Manthan Bhatt**, Director, State Government and Regional Affairs, Advanced Medical Technology Association (AdvaMed)
- **Laura Gunter**, Membership Development Director & Government Affairs, NCBIO (moderator)
- **Mike Mattoon**, Vice President, Federal Government Relations, Biotechnology Innovation Organization (BIO)
- **Doug Peddicord, Ph.D.**, President, Association of Clinical Research Organizations (ACRO)

Sponsored by  **GRIFOLS**



The second day of the Annual Meeting focused on federal policies impacting the life science industry with leaders of national organizations. Again COVID-19 and drug pricing were key topics for the discussion. Manthan Bhatt with AdvaMed discussed the organization’s response to COVID-19 including establishment of an AdvaMed Diagnostic Registry and a Global Supply Chain Taskforce. He reviewed the industry’s efforts to ensure a supply of sterilized products such as ventilators, syringes and other items. He also noted that negotiations are starting on the Medical Device User Fee Amendments (MDUFA) reauthorization in 2022.

Mike Mattoon with BIO said regardless of whoever is President next year, drug pricing will be an issue. He said, “Drug pricing threats make it difficult for companies to raise capital and innovate.” He noted that the public has become more aware of the importance of the industry during the COVID-19 pandemic and the importance of biomanufacturing in North Carolina in helping produce the vaccines and therapeutics.

Doug Peddicord with the Association of Clinical Research Organizations (ACRO) called North Carolina the birthplace of the CRO industry. He discussed innovations during COVID-19 to keep the CRO industry running including use of telemedicine and remote monitoring. He says the pandemic

will result in a new normal for the life science industry as companies learn from experiences in changing design models for trials and working differently with regulatory agencies, and these changes could result in lower pocketbook costs. (See article on upcoming clinical trials forum)

Panelists said it will be interesting to look back one year from now and assess the changes.

Value of Life Sciences – Looking at Innovation in NC

Three companies showcased their cutting edge technologies and a panel discussed the landscape for life companies in North Carolina. Tom Adams, CEO and Co-Founder of Pairwise, kicked off the session with a discussion on how CRISPR can revolutionize produce and crops. He noted that gene editing can reduce producing a pitless cherry to less than five years instead of the normal breeding time of greater than 100 years. In 2022, the company's leafy green product, Veridi, will be available to consumers.

Derek Jantz, Chief Scientific Officer and Co-Founder of Precision BioSciences, talked about "Gene Editing Before It Was Cool." He discussed the growth of the company and its efforts to develop gene editing technology to correct genetic mutations associated with disease. The company has developed an Allogenic CAR T platform using its ARCUS proprietary gene editing platform.

Sean Ekins, Founder and CEO of Collaborations Pharmaceuticals, focused on "Using Machine Learning to Fight Back Against Viruses." He discussed the company's use of real drug discovery intelligence alongside artificial intelligence to develop clinical candidates for rare, neglected and unmet therapeutic needs.

Vivian Doelling, Vice President, Emerging Company Development, NCBiotech, moderated a fireside chat with three local life science leaders. Ed Field, President, BioLabs NC, discussed innovations in cell and gene therapy and the ability to attract outside capital. BioLabs NC now has 44 companies in the space. Doelling noted that NCBiotech is also seeing an increased interest by outside capital companies to invest in North Carolina.

Fireside Chat

- **Ed Field**, President, BioLabs NC
- **Karen LeVert**, Venture Partner, Pappas Capital; President and Co-Founder, Ag TechInventures and Southeast TechInventures
- **Bill Wofford**, Partner, Hutchison PLLC and Co-Founder, Arrivo Bioventures

Sponsored by  **VWI**[™]
part of avantor  **PSCBiotech**[®]
Your Life Science Business Partner

Karen LeVert, Venture Partner, Pappas Capital and President and Co-Founder, Ag TechInventures and Southeast TechInventures, says there is not enough local venture funding for early stage technologies, and she is working on a fund with Pappas Capital that will focus on agriculture. She noted the need also for investments for medical device and drug development companies. Bill Wofford, Partner, Hutchison PLLC and Co-Founder, Arrivo Bioventures, talked about small molecule innovation and innovations/creative research under way at universities in the State. He noted the growth of corporate pharma investments in smaller companies in recent years.

If you have any questions about the program for the annual meeting, please contact [Amber Niebauer](#).

Thank you to our Annual Meeting sponsors.



Platinum and Gold Sponsor Representatives

Top Row Liza Rivera - Fujifilm Diosynth, Jason Kempton - VWR part of Avantor, Brian Stoker - Grifols, Second Row Chandler Conley - PSC Biotech, Vivek Munshi - Bioventus, Scott Sewell - Cook Medical, Bottom Row Keith Burke - Merz Therapeutics

- **Platinum:** [BIO](#), [Bioventus](#), [Cook Medical](#), and [VWR, Part of Avantor](#)
- **Gold:** [FUJIFILM Diosynth Biotechnologies](#), [Grifols](#), [Merz](#), and [PSC Biotech](#)
- **Silver:** [AdvaMed](#), [G1 Therapeutics](#), [GSK](#), [IQVIA Biotech](#), [Liquidia](#), [Mispro Biotech](#), [Nikon](#), [Novo Nordisk](#), [Novozymes](#), [Sage Therapeutics](#), [The Conafay Group](#), and [UCB](#)

[Back to top.](#)

NCBIO Forum on COVID-19 and Clinical Trials

Join us online for a forum on the [COVID Resilient Environment and Virtual Clinical Trials](#) on November 19 from Noon to 1:30 p.m. Our panelists will explore how COVID-19 has affected clinical trials, with an emphasis on how trials are successfully decentralizing.

We'll hear from a clinical research organization with focus on using digital health, novel trial modes, and patient networks and engagement for how a virtual trial can work practically; an attorney connected to the FDA regulation of clinical trials; a gene therapy company with an ongoing clinical trial; and a large pharma manufacturer with years of clinical experience in both vaccines and treatments.

Panelists include:

- **Amy Cramer**, Director, Global Product Development Strategic Partnerships, [Pfizer](#)
- **Tina Papagiannopoulos**, Associate, [Foley Hoag](#)
- **Kristen Pappas**, Associate Director, [bluebird bio](#)
- **David Tripi**, Vice President, Managing Director, [IQVIA](#)

Contact [Amber Niebauer](#), events director, if you have any registration questions. If you would like to sponsor, please contact our membership director, [Laura Gunter](#).

[Back to top.](#)

Virtual Forum – BIO Business Solutions Spotlight

Join us online for a forum on Wednesday, October 28 from Noon to 1:30 p.m. to hear three of our BIO Business Solution (BBS) vendors provide technical insights on several topics.

- **Managing a Single-Use Supply Chain in Support of mAbs, Vaccine, or C> Clinical To Commercial Manufacturing** by **Tim Korwan**, Director, New Product Introduction, Biopharma Production Solutions, VWR Avantor
- **Transitioning From a Paper-Based System to an Electronic Quality Management System** by **Candice Snine**, Business Development Manager, PSC Biotech Corporation
- **Deep Learning and AI–Taking Microscope Imaging and Analysis to the Next Level** by **Ric Villani**, Senior Biosystems Applications Manager, Nikon Instruments

NCBIO members and nonmembers can [register here](#). Please share this with your coworkers in manufacturing, operations, quality and research. It is open to all.

[Back to top.](#)

Series on Diversity in Life Science



Rachael Fones

The second session in the LaunchBio series focused on “Clinical Inequities: How to Increase Diversity in Clinical Trials.” Moderator Rachael Fones, Director, Government & Public Affairs, IQVIA, kicked off the session saying, “There is a lot of hope on this topic, but it is going to require a concerted effort and proactive focus.”



Dr. Rose Blackburne

Dr. Rose Blackburne, Executive Medical Director of Global Product Development, PPD, noted this is not a new topic but the global pandemic has brought renewed focus on it. “Diversity means a lot of different things,” and includes racial and ethnic populations as well as children, women and the elderly.

Dr. Ronke Dosunmu, Pediatrician and Founder of Foundation Pediatrics, says it is important to have a physician champion who can educate other physicians about the necessity of clinical trials. She also recommended having established clinical trial sites work with new sites to help with the process.

R’Kes Starling, President & CEO, Reveles Clinical Services, emphasizes the importance of asking participants in diverse populations to be in a clinical trial. “Engage them in a dialogue about the clinical trial and tell them why it is important.” [Click](#) to see a recording of the webinar.

NCBIO is one of five community partners with LaunchBio in hosting “Let’s Talk About:” a webinar series that explores the experiences of People of Color in the Life Sciences. The next events and topics:

- Let’s talk about Implicit Biases & Workplace Tension: How to Develop Your Company Culture. **(Wednesday, Nov. 11)**
- Let’s talk about How Life science is Addressing Race and Inclusivity. **(Wednesday, Dec. 9)**

[Register here](#) for upcoming webinars.

[Back to top.](#)

One Small Business Fund SBIR Matching Grants Available, Apply by December 1

Any bioscience or other technology company in North Carolina that has received a specified type of federal grant for research and development has until Dec. 1 to apply for matching state funds through the [One NC Small Business Program](#).

The state’s General Assembly and Gov. Roy Cooper appropriated \$1.5 million to the One NC Small Business Program in September, using federal funds designated to ease the economic impacts of the COVID-19 pandemic. [More](#)

[Back to top.](#)

First Flight Venture Center Wins Federal Award



First Flight Venture Center (First Flight) has been awarded a \$125,000 grant by the U.S. Small Business Administration (SBA), Office of Innovation and Technology, Federal and State Technology (FAST) Partnership Program. First Flight, for the third year in a row, is one of just 24 recipient organizations recognized nationwide to provide support to science-focused entrepreneurs developing innovative and disruptive technologies.

FAST seeks to improve outcomes in the Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Programs for underserved communities by increasing participation from women-owned, rural-based, and socially/economically disadvantaged small businesses. First Flight is delighted to again partner with Eva Garland Consulting (EGC), a nationally recognized grant-writing firm with expertise in the SBIR/STTR program, to deliver the First Flight FAST 2020/21 award program.

[Back to top.](#)



AdvanSE Life Sciences Virtual Conference Nov 9-13

SEMDA and SEBIO have merged to form Southeast Life Sciences, connecting biopharma, medical device, diagnostics, and digital health industries with investors, potential partners, and the resources they need. They are hosting the [AdvanSE Life Sciences Conference](#). Check out the [agenda](#) and [register](#).

[Back to top.](#)



At the National Level

The Pharma 1000

The Torrey report released last month provides a snapshot of the global pharmaceutical industry in September 2020 and compares it to the industry in 2015. The report ranks the top 1,000 companies by value to facilitate a comparison of the economic value of a highly diverse group of companies. [More](#)

The Virtual MedTech Conference Wraps-Up

The Virtual MedTech Conference, powered by AdvaMed, finished three days of livestream events, drawing together leaders from in- and outside the medical technology industry hailing from 33 countries and 40 states. Some highlights from The Virtual MedTech Conference include:

- AdvaMed bestowing its 2020 Lifetime Achievement award to former Guidant CEO Ronald “Ron” W. Dollens
- Engaging plenary sessions featuring NBA legend Magic Johnson, FDA Commissioner Dr. Stephen Hahn, Maryland Gov. Larry Hogan, as well as popular CDRH and CMS Town Halls

[Click](#) for more. Next year’s event is scheduled for September 2021.

BIO Investor Forum Focuses on Markets, Pandemic and Other Topics

“Despite challenges in the rest of the economy, 2020 has been the strongest on record for biotech—record IPOs, record follow-on offerings (or FPOs), significant uptick in private investment, significant new fund formation, and strong capital formation,” according to panelists focusing on the market outlook during the BIO Investor Forum.

Looking at infectious diseases and the pandemic, “This is the beginning of a new normal for us.” said Merck’s Julie Gerberding. “This is not the once in a 100 years pandemic. We’re likely to see emergence of important, potentially global threats because of the nature of our world.”

[Click](#) to find out more about the forum, and [click](#) to hear some of presentations.

JP Morgan Healthcare Event January 11-14

With the J.P. Morgan Healthcare Conference going digital for 2021, so too will BIO, offering **BIO One-on-One Partnering** —the same system used at all BIO partnering events—as your virtual partnering and business development companion during JPM Week.

[Registration](#) is now open. BIO members receive complimentary access, and non-member rates start at just \$150. For additional information, please visit bio.org/jpm.

[Back to top.](#)

Member News

To be included in Member News, send information about your organization to [Brenda Summers](#).

[Aerie Pharmaceuticals, Inc.](#) announced that the FDA has reviewed the Investigational New Drug Application (IND) for AR-15512 (TRPM8 agonist) eye drop for dry eye and it is now in effect, allowing Aerie to initiate clinical studies in the treatment of dry eye. Aerie expects to initiate a Phase 2b clinical study in the fourth quarter of 2020. [More](#)

[AskBio](#) Co-Founder and CEO Sheila Mikhail has been named to the *Inc. Female Founders 100*. [More](#)

[Baebies](#) has been named a finalist for the 2020 American Association for Clinical Chemistry's (AACC) Disruptive Technology Award for FINDER, a near-patient testing platform. As a growth-stage company developing diagnostic products to provide a healthy start for children everywhere, Baebies FINDER tests for diseases from low blood volume (50 μ L) with a turn-around time of approximately 15 minutes after sample introduction. [More](#)

[Cook Medical](#) announced that the U.S. Centers for Medicare and Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for Hemospray Endoscopic Hemostat. Effective October 1, 2020, the designation provides eligible hospitals with incremental reimbursement for Hemospray for up to three years. [More](#)

[EternaTear](#), developer of a next-generation, over-the-counter (OTC), preservative-free artificial tear for dry eye sufferers, announced it has completed its oversubscribed Series A round of financing. [More](#)

[G1 Therapeutics, Inc.](#) announced that effective January 1, 2021, Mark Velleca, M.D. Ph.D., will transition to the role of senior advisor and continue to serve as a member of the G1 Board of Directors. Jack Bailey, a member of the company's board, has been named as G1's next Chief Executive Officer. [More](#)

[Grifols](#) announced that its anti-SARS-CoV-2 hyperimmune globulin, a potential treatment for COVID-19, has started a randomized controlled clinical trial to test its safety, efficacy and tolerability. [More](#)

[IQVIA](#), in scientific partnership with the U.S. Food and Drug Administration, will provide agile analytics from IQVIA's CARE Project COVID-19 registry to support better understanding of how people in the community are affected by exposure to the coronavirus. [More](#)

[Kymanox](#) announced the addition of two new executives. Evan Edwards has joined as Principal Executive Advisor and QuynhNhu Nguyen as Director of Human Factors. These new hires bring a breadth of experience which build upon Kymanox's experience in Human Factors and Combination Products including usability, engineering program execution and management, product and process development, quality, regulatory, strategy, clinical and medical affairs, and risk mitigation. [More](#)

[Locus Biosciences](#) announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) to co-fund development of LBP-EC01, a CRISPR Cas3-enhanced bacteriophage (crPhage) product that will target *Escherichia coli* (*E. coli*) bacteria causing recurrent urinary tract infections (UTIs). [More](#)

[Merck](#) announced it will construct a new manufacturing facility to significantly expand its production capacity for TICE BCG (BCG Live For Intravesical Use), a medicine for the treatment of certain forms of bladder cancer. The new facility will be part of the existing Maurice R. Hilleman Center for Vaccine Manufacturing in Durham, North Carolina. The facility is expected to create about 100 new jobs locally. [More](#)

[Mycovia Pharmaceuticals, Inc.](#) ("Mycovia") announced that the last patient has completed their final visit in Mycovia's Phase 3 pivotal clinical trials of oteseconazole (VT-1161) in patients with recurrent

vulvovaginal candidiasis (RVVC). Vulvovaginal candidiasis (VVC) is a common disorder, with nearly 75 percent of all adult women having had at least one “yeast infection” in their lifetime. [More](#)

[Novan, Inc.](#) announced positive in vitro results showing the potential efficacy of its NITRICIL platform technology as an antiviral against SARS-CoV-2, the virus that causes COVID-19. [More](#)

[PPD, Inc.](#) was recognized for leadership at the 13th annual Vaccine Industry Excellence (ViE) Awards during the 2020 World Vaccine Congress. [More](#)

[Shattuck Labs, Inc.](#), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of cancer and autoimmune disease, announced the closing of its upsized initial public offering of 13,664,704 shares of common stock, which includes the exercise in full by the underwriters of their option to purchase up to 1,782,352 additional shares of common stock, at a public offering price of \$17.00 per share. [More](#)

[Syneos Health](#) announced that it was awarded the Society for Clinical Research Sites (SCRS) Eagle Award, sweeping the CRO category for the fourth consecutive year. [More](#)

[Back to top.](#)

BIO Business Solutions



In 2019, BIO saved 4,300 companies nearly \$430 million through BIO Business Solutions with volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more.

NCBIO members, you are eligible for BIO Business Solutions volume-based discounts and favorable contract terms on lab supplies, waste removal, microscopes, shipping, gases, and more. This is a benefit of your NCBIO membership. Review the cost-savings offered by clicking [here](#) and choose the programs you're interested in. Email [Bob Dearth](#) or call 781-716-7555 with your choices and they will get you started. For all the latest news, promos, and event information, follow [BIO Business Solutions on LinkedIn!](#)



Monetize your Assets and Maximize Your ROI

BIO's preferred partner American Laboratory Trading (ALT) provides premium refurbished lab equipment with a FREE one-year equipment warranty and surplus strategy services for life sciences companies. Due to the current high demand for refurbished lab equipment, they are kicking off their 4th quarter buying season with aggressive offers for your surplus equipment.

Are one or more of these instruments sitting idle in your lab? Now may be a good time to connect with ALT.

- GC Systems
- Mass Spec/QQQ Systems
- Biosafety Cabinets
- Centrifuges

- Dissolution Systems
- Hoods
- Incubators
- Lyophilizers
- Real-time PCR Systems
- Plate Readers
- Spectrophotometers
- Sterilizers
- Water Baths and Circulators


ALT's process is designed to expedite your request – they can uninstall, pack and ship your equipment, saving you additional time and cost.



New integrations make life easier


Brex and SAP Concur:

The new direct integration with Concur automatically ports Brex card transactions into the Concur expense management platform. [See how it works.](#)



Brex and Xero:

Brex card data automatically syncs with Xero through a standard bank feed you can set up in 3 minutes. [See how it works.](#)



[Back to top.](#)

Calendar

To view full calendar, [click](#).

[BIO Patient & Health Advocacy Summit](#)

Wednesday Oct 28, 2020 - Thursday Oct 29, 2020

... [read more](#)

[Tech Transfer During Critical Times](#)

Wednesday Oct 28, 2020

... [read more](#)

[Virtual BIO Business Solutions Spotlight](#)

Wednesday Oct 28, 2020

... [read more](#)

[Bayh-Dole 40th Anniversary Celebration](#)

Wednesday Oct 28, 2020

... [read more](#)

[Remote Lab Operations Management During Challenging Times](#)

Thursday Nov 5, 2020

... [read more](#)

[Diagnostics in Our Time of Covid-19" Virtual Symposium](#)

Thursday Nov 5, 2020

... [read more](#)

[DHIT Frequency Webinar Series](#)

Friday Nov 6, 2020

... [read more](#)

[Larger than Life Science: NSF & NIH SBIRs Demystified](#)

Friday Nov 6, 2020

... [read more](#)

[Larger than Life Science: Coping with COVID - PPP Loans and Loan Forgiveness](#)

Monday Nov 9, 2020

... [read more](#)

[Let's Talk About Series - Implicit Biases and Workplace Tension: How to Develop Your Company Culture](#)

Wednesday Nov 11, 2020

... [read more](#)

[NCBiotech Ag Tech Professional Forum: Plant Health - No Need to be Salty](#)

Wednesday Nov 11, 2020

... [read more](#)

[COVID Resilient Environment and Clinical Trials](#)

Thursday Nov 19, 2020

... [read more](#)

[DHIT Frequency Webinar Series](#)

Friday Nov 20, 2020

... [read more](#)

North Carolina Biosciences Organization © Copyright 2020

email: bsummers@ncbioscience.net phone: 919-281-8960 web: <http://ncbioscience.net>



NCBIO
P.O. Box 14354
Research Triangle Park
North Carolina 27709